Skip to content

Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer

Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03209336
Acronym
IROT
Enrollment
50
Registered
2017-07-06
Start date
2015-01-01
Completion date
2020-12-30
Last updated
2017-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

Ultra-low rectal cancer, Intersphincteric resection, IORT

Brief summary

To study the application of Intersphincteric Resection(ISR)combined with intraoperative radiation therapy(IORT) for ultra-low rectal cancer,and to broaden the surgical indications of Intersphincteric Resection(ISR. The study is aimed to assess the postoperative acute complication and the short-term acute efficacy on the patients with middle and low rectal cancer by treated with intraoperative radiotherapy,especially those with peritoneal inversion rectal cancer.

Detailed description

Abstract objective: To study the application of Intersphincteric Resection(ISR)combined with intraoperative radiation therapy(IORT) for ultra-low rectal cancer,and to broaden the surgical indications of Intersphincteric Resection(ISR). Methods: Patients, who were diagnosed with ultra-low rectal cancer and had strong desire of preserving anal function, will take part in the research,whose tumor invading the levator ani muscle or above, the diameter less than 6cm, the lower tumor margin away from the anal verge by less than 5cm and away from the dentate line by less than 3cm.They will undergo total mesorectal excision(TME) and ISR combined with IORT and prophylactic ileostomy. Outcomes Measures:The evaluation of short term effects includes complications such as anastomotic leakage, acute radiation injury ,urinary dysfunction ,dysfunction of anal sphincter ,sexual dysfunction ,local recurrence , total life expectancy and expectancy without metastasis. The postoperative pathological examination reported to be moderately differentiated adenocarcinoma .We wili assess their postoperative acute complications and short-term efficacy .Their time of follow up visit wil be 1 year or more.

Interventions

RADIATIONIntraoperative radiotherapy by Intrabeam(Zeiss Meditech,Jena,Germany)

We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.

Sponsors

Second Hospital of Jilin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Inclusion Criteria: * Aged 40 to 80 years old, gender not limited. * Be diagnosed as colorectal cancer by coloscopy. * Patients with middle and low rectal cancer,whose preoperative staging evaluation is T3 ,T4 or N+. * Accept surgery and intraoperative radiotherapy. * Signed informed consent

Exclusion criteria

* the patients whose preoperative evaluation is below T3 stage with middle and rectal cancer. * Active internal bleeding (such as gastrointestinal bleeding), urogenital system, or have not cure of peptic ulcer in four weeks * Severe liver and kidney dysfunction * Intracranial tumor, suspicious aortic dissection, arteriovenous malformation, aneurysm * Thrombolysis treatment in one week * Allergies of thrombolysis drug or contrast * Participated in any clinical trials within three months

Design outcomes

Primary

MeasureTime frameDescription
Decide and record the region of radiotherapyIntraoperationThe operator will confirm and record the range of intrabeam after removal of tumor such as the length and height to modify the dose and the time of intrabeam.
The basic information and medical history achieved (questionnaire)baselineInvestigators will take a overall information about the patients including the physical condition,history of present illness,family genetic history etc;Then the information will be recorded in a format to develop a statistic analysis.

Secondary

MeasureTime frameDescription
Major Adverse Events1 year after operationThe local relapse (pelvic pain, bleeding and intestinal obstruction included)or metastasis will be recorded by the investigator
The short-term complications1 year after operationThe short-term complications(seroma,wound dehiscence and bleeding hematomas)will be followed up by investigator.

Countries

China

Contacts

Primary ContactMin Wang, M.D.
jdeywangmin@163.com(+86)13074373336
Backup ContactWangsheng Xue
907588917@qq.com(+86)17625642616

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026